TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93 | -41.5% | 10,383 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $159 | -15.4% | 10,383 | +23.9% | 0.00% | -50.0% |
| Q1 2023 | $188 | -6.9% | 8,379 | -12.8% | 0.00% | 0.0% |
| Q4 2022 | $202 | -99.9% | 9,611 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $237,000 | +3.5% | 9,611 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $229,000 | +21.8% | 9,470 | +29.9% | 0.00% | +100.0% |
| Q1 2022 | $188,000 | -61.2% | 7,293 | -53.2% | 0.00% | -50.0% |
| Q4 2021 | $484,000 | +132.7% | 15,594 | +103.9% | 0.00% | -75.0% |
| Q4 2020 | $208,000 | – | 7,649 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |